Many studies that followed further demonstrated the anti-tumor activity and promise of 4-1BB agonism, alone or in combination with other therapeutic strategies, in different types of cancer, including lymphoma, hepatocellular carcinoma, and melanoma (58, 59). This evidence concerns the gene TNFRSF9 and melanoma.